Solventum (NYSE:SOLV) Upgraded at Mizuho

Solventum (NYSE:SOLV) was upgraded by research analysts at Mizuho from a “hold” rating to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

A number of other equities analysts have also commented on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Solventum in a research report on Thursday, October 30th. UBS Group reiterated a “neutral” rating on shares of Solventum in a research note on Friday, November 21st. Zacks Research lowered shares of Solventum from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 1st. BTIG Research upgraded shares of Solventum from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a report on Tuesday, December 2nd. Finally, Stifel Nicolaus raised their price target on Solventum from $88.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $90.27.

Solventum Price Performance

Shares of NYSE:SOLV opened at $78.87 on Tuesday. The stock has a market capitalization of $13.68 billion, a P/E ratio of 9.09, a P/E/G ratio of 7.27 and a beta of 0.34. The business has a 50-day moving average of $81.35 and a two-hundred day moving average of $75.63. Solventum has a fifty-two week low of $60.70 and a fifty-two week high of $88.20. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.50 and a quick ratio of 1.14.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, November 6th. The company reported $1.50 EPS for the quarter, beating analysts’ consensus estimates of $1.43 by $0.07. Solventum had a return on equity of 28.01% and a net margin of 18.13%.The business had revenue of $2.10 billion for the quarter, compared to analyst estimates of $2.05 billion. During the same quarter in the prior year, the firm posted $1.64 EPS. The firm’s revenue for the quarter was up .7% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. On average, equities research analysts predict that Solventum will post 6.58 EPS for the current fiscal year.

Solventum announced that its Board of Directors has authorized a share repurchase plan on Thursday, November 20th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the company to purchase up to 7.5% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its shares are undervalued.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SOLV. Vanguard Group Inc. lifted its stake in shares of Solventum by 5.3% in the third quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock valued at $1,249,847,000 after buying an additional 867,837 shares during the period. Independent Franchise Partners LLP increased its stake in Solventum by 27.2% during the third quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock valued at $941,645,000 after acquiring an additional 2,758,174 shares during the period. State Street Corp raised its holdings in Solventum by 1.8% in the 3rd quarter. State Street Corp now owns 6,220,271 shares of the company’s stock valued at $454,080,000 after acquiring an additional 112,261 shares in the last quarter. Davis Selected Advisers lifted its position in shares of Solventum by 0.5% in the 3rd quarter. Davis Selected Advisers now owns 5,517,611 shares of the company’s stock worth $402,786,000 after acquiring an additional 24,950 shares during the period. Finally, Boston Partners lifted its position in shares of Solventum by 26.1% in the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after acquiring an additional 959,543 shares during the period.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.